NICE Endorses Talazoparib Enzalutamide for Pros...

By HEOR Staff Writer

January 23, 2026

NICE Backs Talazoparib-Enzalutamide for Advanced Prostate Cancer The National Institute for Health and Care Excellence (NICE) has recommended talazoparib enzalutamide ...
Trump Economic Revival: Key Policies and Impacts from Davos 2026
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
FDA Updates Labeling on Febrile Seizure Risks in Influenza Vaccine for Children
Guiding Principles for Ethical AI Integration in Drug Development
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
Empowering Leaders at the Global Pharma Executive Course: Navigating Industry...
Johnson & Johnson’s Medicine Access Agreement: Paving the Way for ...
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Thro...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
Childhood Immunization Reforms: Aligning U.S. Schedules with Global Standards
Accelerating Tec-Dara Multiple Myeloma Therapy Review: A Game Changer for Pat...